 | Up a level |
Chia, John W. K. and Segelov, Eva and Deng, Yanhong and Ho, Gwo Fuang and Wang, Wei and Han, Shuting and Sharma, Atul and Ding, Kefeng and Chen, Gong and Jeffery, Mark G. and Tham, Chee Kian and Ahn, Joong Bae and Nott, Louise and Zielinski, Robert and Chao, Tsu-Yi and van Hagen, Tom and Wei, Po-Li and Day, Fiona and Mehta, Shaesta and Yau, Thomas and Peng, Jiewen and Hayes, Theresa M. and Li, Yong and Gandhi, Mihir and Foo, Estelle M. J. and Rahman, Nabilah and Rothwell, Peter and Ali, Raghib and Simes, John and Toh, Han Chong (2025) Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial. Lancet Gastroenterology & Hepatology, 10 (3). pp. 198-209. ISSN 2468-1253, DOI https://doi.org/10.1016/S2468-1253(24)00387-X.
Yang, Tsai-Sheng and Chen, Hong-Hwa and Bo-Wen, Lin and Kim, Tae Won and Kim, Jong Gwang and Ahn, Joong Bae and Lee, Myung-Ah and Lin, Johnson and Ho, Gwo Fuang and Anh, Le Tuan and Temraz, Sally and Burge, Matthew and Chua, Clarinda and Huang, Jason and Park, Young Suk (2023) Prospective, open-label, and observational study of cetuximab for metastatic colorectal carcinoma: The OPTIM1SE study. Asia-Pacific Journal of Clinical Oncology, 19 (6). pp. 672-680. ISSN 1743-7555, DOI https://doi.org/10.1111/ajco.13920.
